ISRG stock sentiment todayIntuitive Surgical, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 88% confidence.
Last updated · cached analysis, refreshes periodically
ISRG
Intuitive Surgical, Inc.Intuitive Surgical remains the undisputed king of robotic surgery with a wide economic moat and a massive recurring revenue engine via its Da Vinci platform.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ISRG. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the rollout of the Da Vinci 5 system and the recovery in elective procedure volumes post-pandemic. Investors are excited about AI-driven surgical analytics and expansion into international markets like China and Europe.
- ·FDA clearance and launch of Da Vinci 5
- ·Robust procedure volume growth exceeding 15%
- ·Anticipation of AI integration in digital surgery
Financial
Exceptional balance sheet with zero debt and over $8 billion in cash/investments. High margins and a 'razor-and-blade' model where 75%+ of revenue is recurring from instruments, accessories, and services.
- ·Gross Margins consistently above 65%
- ·Forward P/E remains high (approx. 60x-70x), reflecting premium quality
- ·Double-digit revenue and EPS growth
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High valuation leaves little room for earnings misses
- ·Increasing competition from MedTech giants
- ·Hospital capital expenditure constraints
Peer temperature
How direct competitors stack up against ISRG right now.
- NEUTRALMDTMedtronic
COLDER — slower growth and legacy baggage, though their Hugo system is a cheaper, credible long-term threat.
See full analysis → - HOTSYKStryker
WARMER — trading at a more attractive valuation while dominating the robotic orthopedic space with Mako.
See full analysis → - COLDJNJJohnson & Johnson
COLDER — diversified conglomerate facing legal overhangs and a slower-to-market robotic platform (Ottava).
See full analysis →
- ISRG+5.5%
- MDT+4.2%
- SYK-6.1%
- JNJ-0.4%
AI-generated analysis for informational purposes only. Not financial advice.